Koji Pharmaceutical-B (02171): Preliminary results of CT0596 were reported at the 67th Annual Meeting of the American Society of Hematology

Zhitong Finance App News, Keji Pharmaceutical-B (02171) announced that the preliminary results of CT0596 (an allogeneic CAR-T cell candidate product targeting BCMA) were reported at the 67th American Society of Hematology (ASH) Annual Meeting.

The preliminary results of the CT0596 IIT study were presented on a poster at the 67th ASH Annual Meeting on December 6, 2025 from 5:30 p.m. to 7:30 p.m. EST. The title “A First-in-Human Study of CT0596 (an allogeneic CAR T cell therapy targeting BCMA) in patients with relapsed/refractory multiple myeloma” (A First-in-Human Study of CT0596, an Allogenetic CAR T-Cell) Therapy Targeting BCMA, in Patients with Relapsed/Refractory Multiple Myeloma)).

CT0596 is a general-purpose CAR-T cell therapy targeting BCMA. It was developed based on the Thank-U Plus™ platform independently developed by Keji Pharmaceuticals. Clinical trials initiated by researchers are currently being carried out in relapsed/refractory multiple myeloma (R/R MM) or plasma cell leukemia (PCL). CT0596 showed initial good safety and encouraging efficacy signals, and expansion of CAR-T cells was observed in all preset-dose groups. In addition to R/R MM, the company plans to further explore other plasma cell tumors and autoimmune diseases driven by autoreactive plasma cells. The company expects to submit an IND application for this type in the second half of 2025.